AstraZeneca says detained China head has lawyer

AstraZeneca says detained China head has lawyer, but company still in dark
AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but the company has very little information about the case, its CEO said on Tuesday.
AstraZeneca says China has detained a senior executive
The company believes Chinese authorities are probing allegations that two current and two former employees had illegally imported cancer drugs.
Pharma Giant AstraZeneca Takes China Probes 'Very Seriously'
British pharmaceutical giant AstraZeneca on Tuesday said it takes "very seriously" China's investigations into potential illegal data collection and drug imports by the group that led to the detention of its China boss.
AstraZeneca CEO says detained China chief has a lawyer but 'we have no information'
AstraZeneca's CEO said on Tuesday that the company's China president Leon Wang, who last month was detained by Chinese authorities, has a lawyer he is in touch with, but "we have no information as a company".
AstraZeneca’s China Head Taken Into Custody by Chinese Authorities: Reports
While it remains unclear why AstraZeneca China President Leon Wang has been detained, news of his arrest comes just days after it was reported that he was under investigation for alleged medical insurance fraud in the country.
Pharma Giant AstraZeneca Says China Chief Detained
Pharmaceutical giant AstraZeneca said that the head of its China operations had been detained, after reports the firm was under investigation for potentially illegal data collection and drug imports.
AstraZeneca's China chief in custody, believes unrelated to insurance probe
AstraZeneca said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not know the reason, it did not believe it was linked to a large health insurance fraud case involving the company.
AstraZeneca talks up US growth as China problems fester
AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid a probe that has battered the drugmaker’s share price.
AstraZeneca chief says group takes China probe ‘very seriously’
AstraZeneca chief executive Pascal Soriot said the company took the detention of its China president “very seriously”, as the drugmaker raised its guidance for a second straight quarter on the back of strong sales of cancer medicines.
FiercePharma2d
AstraZeneca CEO defends corporate oversight, $80B revenue target amid China probes
Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper ...
Benzinga.com2d
AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously'
Guidance: For fiscal year 2024, AstraZeneca forecasts total revenue and core EPS to increase by a high-teens percentage, ...
BioSpace2d
AstraZeneca Dodges China Questions While Raising 2024 Outlook With Strong Q3 Sales
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
Investopedia on MSN9d
AstraZeneca Shares Slide As Execs in China Face Fraud Investigation
AstraZeneca shares declined Tuesday after reports that senior executives in China were potentially implicated in an ...
FTSE 100 Live 12 November: Vodafone and AstraZeneca results fail to revive shares, Metro Bank fined £16m
DCC shares have jumped 17% in the FTSE 100 index after the Dublin-based conglomerate announced plans to focus on its energy ...
AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
Outsourcing-pharma8h
AstraZeneca doubles down on US manufacturing with $3.5 billion investment
AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...
Business Insider22h
AstraZeneca: Overcoming Short-term Challenges with Robust Long-term Potential
Justin Smith has given his Buy rating due to a combination of factors that highlight AstraZeneca’s potential amidst current challenges. Despite concerns surrounding an investigation in China, ...